Addex Reports Top-Line Data From a Successful Phase 2a Clinical Study With …
Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with …
Filed under: drug abuse treatment cost analysis program
Thus, these mGluRs, because of their ability to fine-tune glutamate signaling, appear to be attractive targets for drug treatment. Indeed, industry has been investing in mGluR research for about three decades and research shows that mGluR drugs have …
Read more on Reuters
PropThink: Titan Files NDA on Probuphine; Partner Waits
Filed under: drug abuse treatment cost analysis program
Monday morning, Titan Pharmaceuticals (OTC:TTNP) announced it had filed a New Drug Application (NDA) to the U.S. FDA on Probuphine for the maintenance treatment of opioid dependence in adults patients (Press Release). … In August 2011, Titan hosted a …
Read more on Reuters
Would Legalizing Marijuana Increase Consumption? – Complete video at: fora.tv A panel of advocates debate the potential effects of marijuana legalization on consumption rates of the drug. Cannabis activist Richard Lee argues that legalization decreases marijuana use, while RAND’s Beau Kilmer points out a common misconception related to that argument. —– Will California become the first state to legalize the production and sale of marijuana? November ballot measure Proposition 19 would allow local governments to choose whether and how to regulate and tax marijuana. Some are concerned about legalization’s effect on consumption and public health, while others tout the potential boon to city and state coffers. Besides the jaw-dropping estimated retail price decrease from 0 to per ounce, nothing is really certain about the potential impact of Prop 19. Get informed before the vote — don’t miss advocates of both sides arguing the pros and cons of pushing pot through the legal pipeline. – Commonwealth Club of California Beau Kilmer is codirector of the RAND Drug Policy Research Center. His primary fields of interest are illicit markets, community corrections, drug treatment, and the future of drug testing. Kilmer’s recent work focused on measuring the size of the global drug market for the European Commission and developing indicators to measure the impact of drug enforcement in Europe. His current work focuses on identifying the community-level effects of drug treatment and assessing the cost-effectiveness of an …